Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

NCT04600089 — Phase 2, Completed, 21 participants, Eric Johnson

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Randomized, Double-blind, Placebo-controlled, Study to Identify the Opioid-sparing Effects, and Pain-reduction Potential of Low Dose Ketamine on Patients Undergoing TEVAR Procedures Receiving NCI

RegistryNCT04600089, acronym 2020Ketamine
StatusCompleted
PhasePhase 2
Study typeInterventional; randomized, parallel, masking: quadruple, treatment
Enrollment21 (Actual)
SponsorEric Johnson (Other)
ConditionsDescending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm
InterventionsSaline, Ketamine (Drug)
Datesstart 2020-12-08, primary completion 2025-10-17, completion 2025-10-17, first posted 2020-10-23, last updated 2026-09-21
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Descending Aortic Dissection All trials for Postoperative Pain All trials of Saline All trials of Ketamine

-Summary

The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).

Expand all sections  ·  Collapse all

+Detailed description

Patients undergoing descending aortic repair often experience post-operative pain, and have high post operative opioid requirements. That pain is partially due to the use of naloxone continuous infusion (NCI). NCI is part of a bundled approach used in the first 48 hours post-operatively to prevent spinal cord ischemia, a devastating complication associated with surgical repair of the descending aortic. Data indicate that patients receiving NCI experience elevated post-operative pain scores and increased opioid requirements during the 48-hr post-operative NCI administration, compared to patients not receiving NCI.

Ketamine is an FDA-approved N-methyl D-aspartate (NMDA) antagonist that has been shown to provide adjunctive analgesia and opioid-sparing effects in post-operative surgical patients. At low doses, ketamine provides analgesic benefit without the anesthetic effects seen at higher doses. These doses are commonly referred to sub-dissociative. This study will evaluate whether use of sub dissociative ketamine (SDK) in patients undergoing aortic procedures with the use of NCI will lead to decreased post-operative opioid consumption, and produce improved pain scores in the first 48 hours.

+Arms and interventions

ArmTypeInterventionsDescription
Standard of CarePlacebo comparatorDrug: SalineParticipants in this group will receive standard of care as well as a saline infusion during the study period.
Sub-Dissociative KetamineExperimentalDrug: KetamineParticipants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.
  • Saline (Drug): Saline infusion
  • Ketamine (Drug): Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.

+Outcome measures

Primary outcomes

  • Cumulative Opioid Dose [48 hours]: Total morphine milligram equivalents (MME) will be assessed every 6 hours for 48 hours.

Secondary outcomes

  • Change in Pain [48 hours]: Pain will be assessed using a 10-Point Numerical Pain Scale (as part of standard of care) every hour for the first 24 hours and every two hours for the next 24 hours. Scores range from 0-10; higher scores indicated higher levels of pain.
  • Number of Patients with Ketamine-Induced Delirium [48 hours]: Ketamine-induced delirium will be monitored via the Confusion Assessment Method (CAM-ICU) survey every 8 hours for 48 hours. The CAM-ICU assesses four diagnostic features of delirium and the result is a binary (yes or no) determination.
  • Number of Patients with Uncontrolled Hypertension [48 hours]: Uncontrolled hypertension is defined as a systolic pressure of 160 mmHg despite 3 intravenous antihypertensive agents.

+Eligibility

Sex: All, ages: 18 Years to 90 Years

Inclusion Criteria:

* willing to give informed consent
* scheduled for elective thoracic aorta repair or thoracoabdominal aortic repair
* requires naloxone continuous infusion for spinal prophylaxis

Exclusion Criteria:

* allergy to ketamine, acetaminophen, or fentanyl
* diagnosis of schizophrenia
* history of hydrocephalus or central nervous system mass
* incarcerated individuals
* pregnant or lactating individuals

+Locations (1)

FacilityCityCountryStatus
University of Kentucky Medical CenterLexington, KentuckyUnited States

+Investigators